Exchange: NASDAQ·Updated 01:58 PM EST
ACHV logo

ACHV Achieve Life Sciences Inc.

$6.04
$0.02
(0.33%)
Today
Reported EarningsNov 10
Mkt Cap$623.59M
Vol21,775.00

About ACHV

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
42

Bearish Sentiment

How do you feel about ACHV?

ecoethcon
$ACHV I have a mixed reaction on the recent study released by Achieve. As an investor and one who is concerned about the quality of health care it is amazing news. As a citizen it is disappointing that after all these years in which the data has been uniformly positive on both efficacy and safety fronts that this is taking so long. Gatekeeping comes to mind and it goes right to the heart of how FDA is funded and how it operates. So many people should have been given the opportunity and so many lives could have been saved...the last few years things have been held up by very fixable technicalities. I will just keep investing here and with others do what we can to improve the system...
19
bobtheknob
$ACHV Completion Status: Following the initial engineering batch earlier this year, AchieveRx successfully completed the manufacturing of three full-scale commercial stability batches at Adare's facility. Regulatory Purpose: These three registration/stability batches satisfy the manufacturing and stability data requirements mandated by the FDA following the earlier Complete Response Letter (CRL) regarding the prior third-party contract manufacturer. NDA Impact: Completing these batches clears the primary operational hurdle needed to name Adare as the commercial manufacturer, keeping AchieveRx on track to submit the cytisinicline NDA resubmission before the end of Q4 2026.
10
drdoctor7
$ACHV Vaping Data. The ORCA-OL enrolled 61 adults who vaped exclusively. At the end of the year, 24.6% achieved biochemical evidence of cessation. To my knowledge, these are the first data from a hard-to-treat vaping population by inclusion criteria. Furthermore, the trial continued to report a very favourable side effect profile with increased and prolonged exposure to cytisinicline. Very positive!
7
markwall
$ACHV On October 21, 2026, Achieve Life Sciences presented new 52-week efficacy and safety data for cytisinicline from its open-label ORCA-OL clinical trial at the CHEST 2026 Annual Meeting. The trial evaluated adults who had continued smoking or vaping daily despite prior participation in earlier short-term cytisinicline clinical trials (such as ORCA-2, ORCA-3, or ORCA-1). Participants received 3 mg of cytisinicline three times daily along with behavioral support for up to 52 weeks to study the effects of continuous, long-term exposure and retreatment.
5
Rayvio_News_Filter
$ACHV 🏥 Achieve Life Sciences, Inc. presented 52-week ORCA-OL results showing 39% of participants new to cytisinicline had quit smoking or vaping at one year. Market-relevant event
4
bobtheknob
$ACHV We are not going to get a conference call till we get a major clinical update , like NDA filing, as stated from the last er release.
3
shoc24
$ACHV reported earnings after the close today. GAAP EPS beat estimates: -$0.11 vs. -$0.20 expected, according to Stock Meadow.
2
Bornjever
$ACHV I have held for 6 months and I never imagined that it might take 6-8 months to reconfirm everything!!! Based on what is happening could it take till next June???
1
inmarketswetrust
$ACHV don’t think all the younger vapers think they have a problem yet- they think they’re doing the healthier thing by not smoking- for older smokers, who have been smoking for decades, the best quit rate on the first attempt using achieve drug is still only 32%. Will play a bump in share price around the re submission of NDA by end of year tho. Plus having heavy hitters from VRNA now in key leadership positions gives me hope. Just don’t see nicotine addiction going away. Still a decent catalyst play for now
1
JackFlaps
$ACHV so what does the FDA pause on vouchers mean for ACHV? Did that get squandered in the delay to perform that last clinical study?
SmokeyDuck
$ACHV #howardlindzon according to my Schwab account, Achieve Life Sciences has changed their ticker from $ACHV to $QUIT.

Advertisement|Remove ads.